Abstract:Osteoarthritis (OA) is a widespread joint condition affecting millions globally, presenting a growing socioeconomic burden thus making the development of more effective therapeutic strategies crucial. This review emphasizes recent advancements in lipid-based drug delivery systems (DDSs) for intra-articular administration of OA therapeutics, encompassing non-steroidal anti-inflammatory drugs, corticosteroids, small molecule disease-modifying OA drugs, and RNA therapeutics. Liposomes, lipid nanoparticles, lipidic mesophases, extracellular vesicles and composite systems exhibit enhanced stability, targeted delivery, and extended joint retention, which contribute to improved therapeutic outcomes and minimized systemic drug exposure. Although active targeting strategies hold promise, further research is needed to assess their targeting efficiency in physiologically relevant conditions. Simultaneously, multifunctional DDSs capable of delivering combinations of distinct therapeutic classes offer synergistic effects and superior OA treatment outcomes. The development of such long-acting systems that resist rapid clearance from the joint space is crucial, where particle size and targeting capabilities emerge as vital factors. Additionally, combining cartilage lubrication properties with sustained drug delivery has demonstrated potential in animal models, meriting further investigation in human clinical trials. This review highlights the crucial need for direct, head-to-head comparisons of novel DDSs with standard treatments, particularly within the same drug class. These comparisons are essential in accurately evaluating their effectiveness, safety, and clinical applicability, and are set to significantly shape the future of OA therapy.

Recombinant protein drugs-based intra articular drug delivery systems for osteoarthritis therapy

Intra-Articular Drug Delivery for Osteoarthritis Treatment

Targeted Drug Delivery Strategies for the Treatment of Rheumatoid Arthritis

Polymer particles for the intra-articular delivery of drugs to treat osteoarthritis

Emerging pharmaceutical therapeutics and delivery technologies for osteoarthritis therapy

Intra-articular drug delivery systems for osteoarthritis therapy: shifting from sustained release to enhancing penetration into cartilage

Enhancing retention and permeation of rapamycin for osteoarthritis therapy using a two-stage drug delivery system

Targeted treatment for osteoarthritis: drugs and delivery system

Overcoming barriers for intra-articular delivery of disease-modifying osteoarthritis drugs

Intra-articular nanoparticles based therapies for osteoarthritis and rheumatoid arthritis management

Current Research on Pharmacologic and Regenerative Therapies for Osteoarthritis

A Comprehensive Review of Advanced Drug Delivery Systems for the Treatment of Rheumatoid Arthritis.

Application of Injectable Hydrogels as Delivery Systems in Osteoarthritis and Rheumatoid Arthritis

Harnessing the multifunctionality of lipid-based drug delivery systems for the local treatment of osteoarthritis

Responsive Hydrogel-Based Drug Delivery Platform for Osteoarthritis Treatment

Dehydroepiandrosterone and Experimental Osteoarthritis.

Controlled Stimulus-Responsive Delivery Systems for Osteoarthritis Treatment

Advances in local drug delivery technologies for improved rheumatoid arthritis therapy

A brief review of current treatment options for osteoarthritis including disease-modifying osteoarthritis drugs (DMOADs) and novel therapeutics

Therapeutic Controlled Release Strategies for Human Osteoarthritis

Exploring the translational potential of PLGA nanoparticles for intra-articular rapamycin delivery in osteoarthritis therapy